Mechanism: Triple vs. Single Receptor
The foundational difference is receptor scope. Semaglutide is a selective GLP-1 receptor agonist — it was engineered to mimic the single incretin hormone GLP-1. Retatrutide activates three receptors simultaneously.
Retatrutide (GLP-3 RT)
Semaglutide (Ozempic / Wegovy)
Semaglutide suppresses appetite but doesn't directly drive thermogenesis. Retatrutide's glucagon receptor agonism activates hepatic fat oxidation and thermogenesis independently of appetite suppression — creating a second fat-loss mechanism. This explains why Retatrutide achieves nearly double the weight reduction despite sharing the GLP-1 backbone.
Weight Loss Efficacy
| Metric | Retatrutide (GLP-3 RT) | Semaglutide (Wegovy) |
|---|---|---|
| Phase 3 weight loss | 28.7% at 68 wks | 14.9% at 68 wks |
| ≥20% weight loss responders | >70% | ~15% |
| ≥15% weight loss responders | >80% | ~37% |
| Hepatic fat reduction | Pronounced | Moderate |
| HbA1c reduction (T2D) | Significant | Significant |
| Visceral fat | Pronounced reduction | Moderate reduction |
| Blood pressure | ↓ Favorable | ↓ Favorable |
| Lipids (LDL / TG) | ↓ Significant | ↓ Significant |
Side Effect Comparison
| Effect | Retatrutide (12mg) | Semaglutide (2.4mg) |
|---|---|---|
| Nausea | ~57% | ~44% |
| Vomiting | ~28% | ~25% |
| Diarrhea | ~25% | ~30% |
| Constipation | ~22% | ~24% |
| Heart rate ↑ | +5 bpm | +2 bpm |
| Discontinuation rate | ~16% | ~7% |
| Cardiovascular outcomes trial | Ongoing (TRIUMPH-CV) | Positive (SELECT trial) |
Semaglutide has a more favorable tolerability profile — lower nausea, lower discontinuation, and a completed positive cardiovascular outcomes trial. Retatrutide's additional receptors deliver greater efficacy but also greater adverse event burden, particularly the heart rate elevation from glucagon receptor activation.
Head-to-Head Summary
| Category | Retatrutide | Semaglutide |
|---|---|---|
| Receptors targeted | 3 (GLP-1, GIP, glucagon) | 1 (GLP-1) |
| Phase 3 weight loss | 28.7% | 14.9% |
| FDA approval | Not Approved | FDA Approved |
| Dosing frequency | Once weekly (SC) | Once weekly (SC) |
| GI tolerability | Moderate–High burden | Moderate burden |
| CV outcomes trial | Ongoing | Positive (SELECT) |
| Published literature | Phase 2/3 data | Extensive (approved drug) |
| Research availability | RUO — Available | RUO — Available |
Research Applications
From a research perspective, the two compounds serve different investigational purposes:
Semaglutide
Well-characterized with extensive published literature across GLP-1 receptor pharmacology, appetite regulation, insulin secretion, cardiovascular outcomes (SELECT trial), and neuroprotection. Gold-standard reference compound for single GLP-1 receptor biology research.
Retatrutide (GLP-3 RT)
The most clinically advanced triple agonist, with the largest published Phase 2/3 safety and efficacy dataset in its class. Key research applications:
- Combined GLP-1 + GIP + glucagon receptor pharmacology
- Glucagon receptor-mediated thermogenesis and hepatic fat oxidation
- NASH / hepatic steatosis metabolic models
- Comparative signaling vs. dual agonists (Tirzepatide) and single agonists (Semaglutide)
Evo Peptides carries GLP-3 RT (Retatrutide) and GLP-2 TRZ (Tirzepatide) for comparative metabolic research — ≥99% purity, COA on every batch, same-day shipping from Wisconsin.